Community Acquired Bacterial Pneumonia Cabp Market

DelveInsight’s ‘Community Acquired Bacterial Pneumonia (CABP)–Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of the Community Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Community Acquired Bacterial Pneumonia (CABP) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Community Acquired Bacterial Pneumonia symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Community Acquired Bacterial Pneumonia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Community Acquired Bacterial Pneumonia (CABP) Disease Understanding and Treatment Algorithm

Community Acquired Bacterial Pneumonia (CABP) Overview

Community Acquired Bacterial Pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumoniae being the most common cause worldwide.

 

Symptoms of Community Acquired Bacterial Pneumonia include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Cough typically is productive in older children and adults and dry in infants, young children, and older adults. Dyspnea usually is mild and exertional and is rarely present at rest. Chest pain is pleuritic and is adjacent to the infected area.

 

Although the diagnostic criteria for Community Acquired Bacterial Pneumonia seem relatively straightforward, making the correct diagnosis can be difficult. A thoughtful history and physical examination with close attention to the actual respiratory rate and core temperature, as well as careful interpretation of chest radiographs, are required. This caution is especially true in the elderly. The clinical diagnosis of Community Acquired Pneumonia is made on the basis of respiratory symptoms such as cough, sputum production, dyspnea, chest pain, signs of fever, and hypoxemia, as well as an infiltrate on chest imaging.

 

Some antibiotics have been approved, which will expand the treatment options for Community Acquired Bacterial Pneumonia, particularly in patients with primary complications. Common antimicrobials used to treat Community Acquired Bacterial Pneumonia include macrolides (alone or in combination with β-lactams), amoxicillin (alone or combined with a macrolide), fluoroquinolones, and third-generation cephalosporins combined with a macrolide.

 

Community Acquired Bacterial Pneumonia (CABP) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Community Acquired Bacterial Pneumonia (CABP) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Community Acquired Bacterial Pneumonia (CABP) market report gives a thorough understanding of Community Acquired Bacterial Pneumonia symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Community Acquired Bacterial Pneumonia treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Community Acquired Bacterial Pneumonia (CABP) Epidemiology

The epidemiology division’s Community Acquired Bacterial Pneumonia (CABP) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Community Acquired Bacterial Pneumonia epidemiology segmented as the Total Incident Cases of Community Acquired Bacterial Pneumonia, Severity Specific Incident cases of Community Acquired Bacterial Pneumonia, Gender Specific Prevalence of Community Acquired Bacterial Pneumonia, Age Specific Prevalence of Community Acquired Bacterial Pneumonia, Pathogen Specific Prevalence of Community Acquired Bacterial Pneumonia. The report includes the Incident Community Acquired Bacterial Pneumonia scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Community Acquired Bacterial Pneumonia (CABP) Epidemiology

The epidemiology segment also provides the Community Acquired Bacterial Pneumonia (CABP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM Incident cases of Community Acquired Bacterial Pneumonia (CABP) were 6,961,838 in 2022.

Community Acquired Bacterial Pneumonia (CABP) Drug Chapters

The drug chapter segment of the Community Acquired Bacterial Pneumonia report encloses the detailed analysis of Community Acquired Bacterial Pneumonia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Community Acquired Bacterial Pneumonia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Community Acquired Bacterial Pneumonia (CABP) Emerging Drugs

 

CAL02 (Eagle Pharmaceutical)

CAL02 is a phase II-stage drug that has successfully been tested in ICU patients with severe CAP. Its unique therapeutic approach uses liposomes engineered to neutralize virulence effectors playing a critical role in developing organ failure and fatal complications in severe infections. With the global emergence of antibiotic resistance, antimicrobial lipids formulated in nano-carriers might provide a novel alternative in combatting infectious diseases.

Products detail in the report…

Community Acquired Bacterial Pneumonia (CABP) Market Outlook

The Community Acquired Bacterial Pneumonia market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Community Acquired Bacterial Pneumonia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Community Acquired Bacterial Pneumonia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Community Acquired Bacterial Pneumonia (CABP) market in 7MM is expected to change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Community Acquired Bacterial Pneumonia market in 7MM. The market size of Community Acquired Bacterial Pneumonia in the seven major markets was found to be USD 2,616 million in 2022.

 

The United States Market Outlook

This section provides a total of Community Acquired Bacterial Pneumonia market size and market size by therapies in the United States.

 

The United States accounts for higher CABP market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Community Acquired Bacterial Pneumonia (CABP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Community Acquired Bacterial Pneumonia (CABP) market size and market size by therapies in Japan are also mentioned.

Community Acquired Bacterial Pneumonia (CABP) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Community Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Community Acquired Bacterial Pneumonia (CABP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Community Acquired Bacterial Pneumonia (CABP) key players involved in developing targeted therapeutics.

 

Major players CAL02 (Eagle Pharmaceutical Inc.), Cx611 (Takeda/TiGenix) and others are being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Community Acquired Bacterial Pneumonia emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working on Community Acquired Bacterial Pneumonia domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Community Acquired Bacterial Pneumonia market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Community Acquired Bacterial Pneumonia Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Community Acquired Bacterial Pneumonia (CABP) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Community Acquired Bacterial Pneumonia (CABP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Community Acquired Bacterial Pneumonia  provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Community Acquired Bacterial Pneumonia (CABP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Community Acquired Bacterial Pneumonia (CABP) market

Report Highlights

  • In the coming years, Community Acquired Bacterial Pneumonia (CABP) market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Community Acquired Bacterial Pneumonia (CABP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Community Acquired Bacterial Pneumonia. The launch of emerging therapies will significantly impact the Community Acquired Bacterial Pneumonia  market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Community Acquired Bacterial Pneumonia 
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Community Acquired Bacterial Pneumonia (CABP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Community Acquired Bacterial Pneumonia (CABP) Pipeline Analysis
  • Community Acquired Bacterial Pneumonia (CABP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Community Acquired Bacterial Pneumonia (CABP) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Community Acquired Bacterial Pneumonia (CABP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Community Acquired Bacterial Pneumonia (CABP) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Community Acquired Bacterial Pneumonia (CABP) Market share (%) distribution in 2022, and how would it look in 2032?
  • What would be the Community Acquired Bacterial Pneumonia (CABP) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2032)?
  • What are the market’s key findings across 7MM, and which country will have the largest Community Acquired Bacterial Pneumonia (CABP) market Size during the forecast period (2021–2032)?
  • At what CAGR, the Community Acquired Bacterial Pneumonia (CABP) market is expected to grow by 7MM during the forecast period (2021–2032)?
  • What would be the Community Acquired Bacterial Pneumonia (CABP) market outlook across the 7MM during the forecast period (2021–2032)?
  • What would be the Community Acquired Bacterial Pneumonia (CABP) market growth till 2030, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Community Acquired Bacterial Pneumonia (CABP)?
  • What is the historical Community Acquired Bacterial Pneumonia (CABP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Community Acquired Bacterial Pneumonia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Community Acquired Bacterial Pneumonia (CABP)?
  • Out of all 7MM countries, which country would have the highest Incident Community Acquired Bacterial Pneumonia (CABP) population during the forecast period (2021–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Community Acquired Bacterial Pneumonia (CABP)?
  • What are the current treatment guidelines for treating Community Acquired Bacterial Pneumonia (CABP) in the USA, Europe, and Japan?
  • What are the Community Acquired Bacterial Pneumonia (CABP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Community Acquired Bacterial Pneumonia (CABP)?
  • How many therapies are developed by each company for the treatment of Community Acquired Bacterial Pneumonia (CABP)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Community Acquired Bacterial Pneumonia (CABP)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Community Acquired Bacterial Pneumonia (CABP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Community Acquired Bacterial Pneumonia (CABP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Community Acquired Bacterial Pneumonia (CABP)?
  • What are the global historical and forecasted markets of Community Acquired Bacterial Pneumonia (CABP)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Community Acquired Bacterial Pneumonia (CABP)  market
  • To understand the future market competition in the Community Acquired Bacterial Pneumonia (CABP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Community Acquired Bacterial Pneumonia (CABP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Community Acquired Bacterial Pneumonia (CABP) market
  • To understand the future market competition in the Community Acquired Bacterial Pneumonia (CABP) market

1. Key Insights

2. Report Introduction

3. Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance

3.1. Market Share (%) Distribution Community-Acquired Bacterial Pneumonia (CABP) in 2019

3.2. Market Share (%) Distribution of Community-Acquired Bacterial Pneumonia (CABP) in 2032

4. Executive Summary of Community-Acquired Bacterial Pneumonia (CABP)

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Pathophysiology

5.4. Signs and Symptoms of CABP

5.5. Clinical Characteristics

5.6. Immunology & Risk Factors

5.7. Diagnosis

5.8. Prognosis

5.9. Diagnostic Biomarkers for CABP

6. Treatment and Management

6.1. Antibiotic therapy

6.2. Diuretics

6.3. Corticosteroids

6.4. Later management

6.5. Diagnostic and Treatment Guidelines

6.5.1. The American Thoracic Society and the Infectious Diseases Society of America

6.5.2. NICE

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Total Incident Patient Population of Community-Acquired Bacterial Pneumonia (CABP)

7.3. Assumptions and Rationale

7.4. The United States

7.4.1. Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the United States

7.4.2. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the United States

7.4.3. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the United States

7.4.4. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in the United States

7.4.5. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in the United States

7.5. The EU-5

7.5.1. Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5

7.5.2. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the EU-5

7.5.3. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the EU-5

7.5.4. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in EU-5

7.5.5. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in EU-5

7.6. Japan

7.6.1. Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in Japan

7.6.2. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in Japan

7.6.3. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in Japan

7.6.4. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in Japan

7.6.5. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in Japan

8. Patient Journey 1

9. Patient Journey 2

10. Marketed Therapies

10.1. Lefamulin (Xenleta): Nabriva Therapeutics

10.1.1. Product Description

10.1.2. Regulatory Milestones

10.1.3. Other Developmental Activities

10.1.4. Clinical Development

10.1.5. Product Profile

10.2. Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Other Developmental Activities

10.2.4. Clinical Development

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. Ceftaroline fosamil (Teflaro): Forest Pharmaceuticals

10.3.1. Drug Description

10.3.2. Regulatory Milestones

10.3.3. Other Development Activities

10.3.4. Clinical Development

10.3.5. Clinical Trials Information

10.3.6. Safety and efficacy

10.3.7. Product Profile

10.4. Linezolid (Zyvox): Pfizer

10.4.1. Drug Description

10.4.2. Regulatory Milestones

10.4.3. Clinical Development

10.4.4. Clinical Trials Information

10.4.5. Product Profile

10.5. Omadacycline (NUZYRA): Paratek Pharmaceuticals

10.5.1. Drug Description

10.5.2. Regulatory Milestones

10.5.3. Other Development Activities

10.5.4. Clinical Development

10.5.5. Clinical Trials Information

10.5.6. Safety and efficacy

10.5.7. Product Profile

10.6. Telavancin (Vibativ): Cumberland Pharmaceuticals Inc./Theravance Biopharma

10.6.1. Drug Description

10.6.2. Regulatory Milestones

10.6.3. Other Development Activities

10.6.4. Clinical Development

10.6.5. Clinical Trials Information

10.6.6. Safety and efficacy

10.6.7. Product Profile

10.7. Ceftolozane/Tazobactam (Zerbaxa): Merck Sharp & Dohme Inc./Cubist Pharmaceuticals LLC

10.7.1. Drug Description

10.7.2. Regulatory Milestones

10.7.3. Clinical Development

10.7.4. Clinical Trials Information

10.7.5. Safety and efficacy

10.7.6. Product Profile

10.8. Imipenem/Cilastatin/Relebactam (Recarbrio™): Merck Sharp and Dohme

10.8.1. Product Description

10.8.2. Regulatory Milestones

10.8.3. Clinical Development

10.8.4. Safety and Efficacy

10.8.5. Product Profile

10.9. Cefiderocol ( Fetroja®): Shionogi Inc.

10.9.1. Product Description

10.9.2. Regulatory Milestones

10.9.3. Clinical Development

10.9.4. Safety and Efficacy

10.9.5. Product Profile

10.10. Ceftazidime/Avibactam (Avycaz): Allergan/Pfizer

10.10.1. Product Description

10.10.2. Regulatory Milestones

10.10.3. Other Developmental Activities

10.10.4. Clinical Development

10.10.5. Safety and Efficacy

10.10.6. Product Profile

11. Emerging Drugs

11.1. CAL02: Eagle Pharmaceutical Inc/Combioxin SA

11.1.1. Drug Description

11.1.2. Other Development Activities

11.1.3. Clinical Development

11.1.4. Clinical Trials Information

11.1.5. Safety and efficacy

11.1.6. Product Profile

11.2. Cx611: Takeda/TiGenix

11.2.1. Drug Description

11.2.2. Other Development Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and efficacy

11.2.6. Product Profile

12. Other Therapies: Generics

12.1. Amoxicillin

12.2. Azithromycin

12.3. Clarithromycin

12.4. Doxycycline

12.5. Moxifloxacin

12.6. Vaccine

12.6.1. Prevnar 13

12.6.2. Vaxneuvance

13. Community-Acquired Bacterial Pneumonia: 7 Major Market Analysis

13.1. Key Findings 

13.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the 7 MM

13.3. Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies In 7MM

14. Market Outlook

14.1. The United States Market Size

14.1.1. Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States

14.1.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the United States

14.2. The EU-5 Market Size

14.2.1. Total Market size of Community-Acquired Bacterial Pneumonia (CABP) in EU-5

14.2.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) of Therapies in EU-5

14.3. Japan Market Size

14.3.1. Total Market size of Community-Acquired Bacterial Pneumonia (CABP) in Japan

14.3.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in Japan

15. KOL Views

16. Unmet Needs

17. SWOT Analysis

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Community-Acquired Bacterial Pneumonia (CABP), Market, Epidemiology, and Key Events (2019–2032)

Table 2: Incidence of Community-Acquired Bacterial Pneumonia (CABP) in 7MM (2019–2032)

Table 3: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the United States (2019–2032)

Table 4: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the United States (2019–2032)

Table 5: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the United States (2019–2032)

Table 6: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in the United States (2019–2032)

Table 7: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in the United States (2019–2032)

Table 8: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in EU-5 (2019–2032)

Table 9: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the EU-5 (2019–2032)

Table 10: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the EU-5 (2019–2032)

Table 11: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in EU-5 (2019–2032)

Table 12: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in EU-5 (2019–2032)

Table 13: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in Japan (2019–2032)

Table 14: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in Japan (2019–2032)

Table 15: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in Japan (2019–2032)

Table 16: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in Japan (2019–2032)

Table 17: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in Japan (2019–2032)

Table 18: Ceftaroline fosamil, Clinical Trial Description, 2022

Table 19: Linezolid, Clinical Trial Description, 2022

Table 20: Omadacycline, Clinical Trial Description, 2022

Table 21: Vibativ, Clinical Trial Description, 2022

Table 22: Zerbaxa, Clinical Trial Description, 2022

Table 23: CAL02, Clinical Trial Description, 2022

Table 24: Cx611, Clinical Trial Description, 2022

Table 25: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in USD Million in 7MM (2019–2032)

Table 26: 7 Major Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in USD Million (2019–2032)

Table 27: United States Market Size of Community-Acquired Bacterial Pneumonia (CABP) in USD Million (2019–2032)

Table 28: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the US in USD Million (2019–2032)

Table 29: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5 in USD Million (2019–2032)

Table 30: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the EU-5 in USD Million (2019–2032)

Table 31: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in Japan in USD Million (2019–2032)

Table 32: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in Japan in USD Million (2019–2032)

List of Figures

Figure 1: Types of Bacterial Pneumonia

Figure 2: Etiology of Community-acquired Pneumonia

Figure 3: Summary of the diagnostic approach to acute cough illness in ambulatory patients.

Figure 4: Chest radiograph demonstrating lobar pneumonia

Figure 5: Clinical decision rules

Figure 6: Incident Patient Population of Community-Acquired Bacterial Pneumonia (CABP) in 7MM (2019–2032)

Figure 7: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the United States (2019–2032)

Figure 8: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the United States (2019–2032)

Figure 9: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the United States (2019–2032)

Figure 10: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in the United States (2019–2032)

Figure 11: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in the United States (2019–2032)

Figure 12: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5 (2019–2032)

Figure 13: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the EU-5 (2019–2032)

Figure 14: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the EU-5 (2019–2032)

Figure 15: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in EU-5 (2019–2032)

Figure 16: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in EU-5 (2019–2032)

Figure 17: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in Japan (2019–2032)

Figure 18: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in Japan (2019–2032)

Figure 19: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in Japan (2019–2032)

Figure 20: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in Japan (2019–2032)

Figure 21: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in Japan in 000's (2019–2032)

Figure 22: 7 Major Market Size of Community-Acquired Bacterial Pneumonia (CABP) in USD Million (2019–2032)

Figure 23: 7 Major Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in USD Million (2019–2032)

Figure 24: Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States, USD Million (2019–2032)

Figure 25: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the US in USD Million (2019–2032)

Figure 26: Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5, USD Million (2019–2032)

Figure 27: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the EU-5 in USD Million (2019–2032)

Figure 28: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in Japan, USD Million (2019–2032)

Figure 29: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in Japan in USD Million (2019–2032)

Nabriva Therapeutics
Melinta Therapeutics
Wakunaga Pharmaceutical
Forest Pharmaceuticals
Pfizer
Paratek Pharmaceuticals
Cumberland Pharmaceuticals Inc.
Theravance Biopharma
Merck Sharp & Dohme Inc.
Cubist Pharmaceuticals LLC
Shionogi Inc.
Allergan
Eagle Pharmaceutical Inc
Combioxin SA
Takeda
TiGenix

 

Forward to Friend

Need A Quote